Cognition Therapeutics, Inc. (CGTX)
| Market Cap | 115.27M +482.3% |
| Revenue (ttm) | n/a |
| Net Income | -23.49M |
| EPS | -0.32 |
| Shares Out | 89.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 353,759 |
| Open | 1.270 |
| Previous Close | 1.280 |
| Day's Range | 1.245 - 1.290 |
| 52-Week Range | 0.222 - 3.830 |
| Beta | 1.39 |
| Analysts | Strong Buy |
| Price Target | 3.33 (+158.14%) |
| Earnings Date | May 6, 2026 |
About CGTX
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins including β-amyloid, or Aβ and ɑ-synuclein which is in Phase 2 clinical studies for the treatment of Alzheimer’s disease and Mild Cogni... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for CGTX stock is "Strong Buy." The 12-month stock price target is $3.33, which is an increase of 158.14% from the latest price.
News
Cognition Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Preparations are underway for Phase III trials of zervimesine, focusing on DLB psychosis after strong Phase II results and regulatory feedback. The Alzheimer's START trial is fully enrolled, with results expected in Q3 2027, and both programs maintain a favorable safety profile.
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Com...
Cognition Therapeutics CEO Issues Letter to Shareholders
Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHAS...
Cognition Therapeutics Earnings Call Transcript: Q4 2025
Prioritizing zervimesine for DLB psychosis after strong phase II results, with registrational trial planning underway and positive regulatory feedback. Cash runway extends through Q2 2027, and Alzheimer's program continues with START trial results expected in 2027.
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
-Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 - - Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y.
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Com...
Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
PURCHASE, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative d...
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
We believe regulatory strategy expedites development of potential first treatment to address DLB psychosis We believe regulatory strategy expedites development of potential first treatment to address ...
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
PURCHASE, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative di...
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disord...
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies
- Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo - - Zervimesine exhibited meaningful improvement in behavioral, functiona...
Cognition Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
CT1812 demonstrated broad efficacy in DLB and Alzheimer's, especially in patients with low p-tau217, and is advancing to Phase 3 with regulatory support for composite endpoints and a six-month trial. The oral drug is well tolerated and may expand to other neurodegenerative indications.
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
- Seeking Alignment with European Medicines Agency (EMA) at February 2026 Meeting - - Actively Evaluating Strategy Across DLB and Alzheimer's Disease -
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference
PURCHASE, N.Y., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, ann...
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease
Study conducted in collaboration with the Alzheimer's Clinical Trials Consortium Study conducted in collaboration with the Alzheimer's Clinical Trials Consortium
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
- $30 Million Registered Direct Offering Support Next Stage of Development for Zervimesine (CT1812) - - Aligned with U.S. FDA on Registrational Path for Zervimesine - - Expanded Access Program for Dem...
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target
PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disor...
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative d...
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
- The offering was made to two new fundamental institutional investors - - The Company intends to use the net proceeds to fund preparation for our Phase 3 programs of zervimesine in neurodegenerative ...
Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative di...
Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease
- Cognition and FDA align on enriched population, study design, and endpoints - PURCHASE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX...
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease
- Zervimesine's impact on debilitating DLB behavioral symptoms highlighted in podium presentation - - Plasma p-tau217 levels can identify Alzheimer's patients most likely to benefit from zervimesine t...
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease
In Vitro Experiments Showing Protection of Neurons under Disease Conditions Support Proteomics Biomarker Analysis from Phase 2 SEQUEL Study In Vitro Experiments Showing Protection of Neurons under Dis...
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC
- Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms as compared to placebo...
Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease
PURCHASE, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disord...